TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for inclusion / randomization into this study, the subjects must fulfill all of the following criteria (if there is no inclusion phase, the inclusion criteria will be considered as inclusion criteria for randomization):~* Written consent form signed by the parents / legal guardian, and child if possible~* Subject born SGA and receiving a r-hGH therapy for this pathology~* Recombinant human growth hormone (r-hGH) started at the maximal chronological age of 7 years for girls and 8 years for boys~* Treatment with r-hGH started for at least 30 months and less than 36 months at 0.057 mg/kg/day~* Height gain during the first 2 years of GH treatment \> 1 SD compared with the initial value~Exclusion Criteria:~To be eligible for inclusion in this study the subjects must not meet any of the following criteria:~* Known hypersensitivity to Somatropin or any of the excipients~* Active neoplasia (either newly diagnosed or recurrent)~* Intracranial hypertension~* Known diabetes mellitus~* Proliferative or preproliferative diabetic retinopathy~* Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion~* Obesity defined as degree 1 on the corpulence curves~* Precocious puberty~* Pubertal status: Tanner breast development stage \> 2 for girls, and testicular volume \> 4 milliliter (mL) or testicular length \> 3 centimeter (cm) and/or testosterone value \>1 nanomole/liter \[nmol/L\] (0.29 gram/mL \[g/mL\]) for boys For girls \> 9 years and Tanner breast development stage 1: uterine size \> 35 millimeter (mm)~* Severe chronic concomitant illness such as chronic renal failure, cystic fibrosis~* Concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment~* Participation to any clinical study within the 30 days preceding study entry

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Saizen® 0.057 mg/kg/day (Type: EXPERIMENTAL): Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than \[\<\] -2 SDS or greater than \[\>\] -2 SDS)
- Saizen® 0.035 mg/kg/day (Type: EXPERIMENTAL): Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (\< -2 SDS or \> -2 SDS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma (MM)~  * Previously untreated asymptomatic disease~ * No requirement for immediate chemotherapy for active MM, such as hypercalcemia from myeloma or painful bone lesions~* No solitary plasmacytoma~* Measurable or evaluable disease as defined by one of the following:~  * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis~ * More than 200 mg of monoclonal protein in the urine by 24-hour electrophoresis~ * Measurable soft tissue plasmacytoma by physical exam with ruler or by MRI or positron emission tomography/CT scan~    * If the only measurable lesion is the plasmacytoma, it must be ≥ 1.5 cm in 1 dimension~* Must have ≥ 10% plasma cells as measured on the bone marrow aspirate, bone marrow biopsy, or labeling index~* No amyloidosis~PATIENT CHARACTERISTICS:~* Performance status 0-2~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 8.0 g/dL~* Creatinine ≤ 2.0 mg/dL (elevation above normal range should not be felt to be related to myeloma)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 methods of effective contraception 4 weeks before, during, and for 4 weeks after completion of study treatment~* No uncontrolled infection~* No other active malignancy~* No New York Heart Association class III or IV heart disease~* No pre-existing neuropathy ≥ grade 2~* No concurrent major dental work~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior corticosteroids (for nonmalignant disorders) allowed~* Prior therapy with experimental agents not shown to have significant activity in MM, such as clarithromycin, dehydroepiandrosterone, and anakinra allowed~* No prior thalidomide or corticosteroids for MM~* No more than 3 doses of IV zoledronate or pamidronate within the past 12 months~* At least 3 months since prior radiotherapy, including radiotherapy for solitary plasmacytoma~* No concurrent oral bisphosphonate therapy for osteoporosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: Thal/ZLD (Type: EXPERIMENTAL): Thalidomide (Thal) + Zolendronic acid (ZLD)
- Arm II: ZLD (Type: EXPERIMENTAL): Zoledronic acid (ZLD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Serum Pepsinogen for Prediction of Metachronous Gastric Neoplasm

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patients who tested serum PG concentration test and H. pylori status at the time of ESD and revealed pathologically complete en bloc resection after ESD for EGC.~Exclusion Criteria:~* previous history of ER; proven pathologically incomplete resection or lympho-vascular invasion on the resected ESD specimen; additional treatment after ESD; and follow-up loss less than 2 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Negative H. pylori group (Type: None): The participants revealed negative findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
- Previous H. pylori infection group (Type: None): The participants revealed positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
- Eradicated H. pylori group (Type: None): The participants revealed to success for H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
- Persistent H. pylori group (Type: None): The participants revealed to fail in H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients hospitalized for chemotherapy or blood/bone marrow transplant.~2. Age 20 - 75~3. Not currently regularly taking any prescribed sleeping pill more often than 4x/week.~4. Can tolerate oral medication.~Exclusion Criteria:~1. Patients with a current history of substance abuse~2. Patients with a history of allergic response to Lunesta.~3. Patient who require additional oral or parenteral opioids after starting PCA opioid treatment.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- eszopiclone (Type: ACTIVE_COMPARATOR): active drug
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizoaffective disorder~* Experiencing an acute exacerbation of psychotic symptoms~* A score of \>=4 on at least 3 of the following 7 PANSS items: Delusions (P1), Hallucinatory behavior (P3), Excitement (P4), Hostility (P7), Tension (G4), Uncooperativeness (G8), and Poor Impulse Control (G14)~* A score of \>=16 on YMRS and/or a score of \>=16 on the HAM-D-21~* Healthy based on physical examinations, electrocardiogram (ECG), laboratory tests, medical history, and vital signs measurements~Exclusion Criteria:~* A primary active mental illness diagnosis other than schizoaffective disorder~* Have attempted suicide within 12 months or are at imminent risk of suicide or violent behavior~* Subjects with first episode of psychosis~* Received electroconvulsive therapy in the past 3 months~* History of hypersensitivity to or intolerance of paliperidone, risperidone, or 20% Intralipid (placebo)~* Received long-acting antipsychotic medication within 2 injection cycles~* Received therapy with clozapine within 3 months~* A history of neuroleptic malignant syndrome~* Previous history of lack of response to antipsychotic medication~* Subjects receiving therapy with antidepressants or mood stabilizers that has been initiated and/or changed in dose \<30 days prior to screening~* Receiving therapy with carbamazepine~* Receiving therapy with monoamine oxidase inhibitors~* Pregnant, breast-feeding, or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months
- 002 (Type: PLACEBO_COMPARATOR): Placebo monthly by i.m. injection for 15 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years.~* Any sex.~* Type Ι or ΙΙ DM,~* recent diabetic VH which is causing vision impairment, precluding complete PRP and needing treatment.~* BCVA is less than 20/70 (log MAR BCVA 0.6) and better than 20/1000 (log MAR BCVA 1.7).~Exclusion Criteria:~* Tractional retinal detachment.~* Previous PRP.~* History of anti VEGF therapy within the past two months.~* Neovascular glaucoma~* Subhyaloid hemorrhage.~* Vitreomacular traction.~* Diabetic macular edema .~* Patients with systemic contraindications for anti VEGF or unstable medical conditions as uncontrolled hypertension (persistently above 180/110 mmhg) or recent thromboembolic event within the past six months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: ACTIVE_COMPARATOR): Intravitreal injection of Aflibercept followed by panretinal photocoagulation.
- Group II: Early vitrectomy. (Type: ACTIVE_COMPARATOR): Early vitrectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years with symptomatic hemorrhoidal disease grade II and III (Goligher's classification)~* Refractory to conservative therapy (dietary modification, intestinal transit modifiers, topical and phlebotonic medications) for a period of not less than 4 weeks~Exclusion Criteria:~* Cirrhosis~* Pregnant or breast-feeding women~* Known allergy to polidocanol~* Another perianal disease that can cause symptoms similar to hemorrhoidal disease~* Colorectal malignancy~* Concomitant presence of external hemorrhoidal disease and/or hemorrhoidal thrombosis - - Office or surgical treatment for hemorrhoids within 6 months prior to inclusion~* Antiplatelet or hypocoagulant medication~* Hematological disorders~* Immunosuppressive states~* Inflammatory bowel disease~* Patients unable to have general or spinal anesthetic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Polidocanol foam sclerotherapy (Type: ACTIVE_COMPARATOR): Patients submitted to polidocanol foam sclerotherapy
- Doppler-guided hemorrhoidal artery ligation (Type: ACTIVE_COMPARATOR): Patients submitted to doppler-guided hemorrhoidal artery ligation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or nonpregnant female patients \>18 years of age.~2. Has a clinical diagnosis of Retinal Vein Occlusion (RVO) in the study eye.~3. Best-Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score ≥ 20 (20/400 Snellen equivalent), and ≤75 in the study eye (20/32 Snellen equivalent).~4. Central Subfield Thickness (CST) ≥310 microns measured by Spectral Domain Optical Coherence Tomography (SD-OCT) in the study eye.~Exclusion Criteria:~1. Intravitreal (IVT) injection of anti-VEGF: Bevacizumab (Avastin; Genentech, South San Francisco, CA, USA/Roche, Basel, Switzerland) or ranibizumab (Lucentis; Genentech Inc., South San Francisco, CA, USA) within 1 month and aflibercept (Eylea®; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA, and Bayer HealthCare Pharmaceuticals, Berlin, Germany) within 2 months in the study eye.~2. Intraocular or periocular corticosteroid injection within 3 months, dexamethasone implant (Ozurdex, Allergan, Dublin, Ireland) within 6 months, Retisert (Bausch and Lomb, Bridge water, NJ) within 1 year, or fluocinolone acetonide implant (Iluvien, Alimera Sciences, Alpharetta, GA) within 3 years in the study eye.~3. Macular laser photocoagulation treatment in the study eye.~4. Topical ophthalmic nonsteroidal anti-inflammatory drugs in the study eye within a month.~5. Any significant media opacity that could hinder the evaluation of the retina or ocular condition causing decreased vision other than RVO.~6. IOP \>22 mm Hg, or history of steroid-induced ocular hypertension; uncontrolled glaucoma.~7. Past vitreoretinal or glaucoma surgery in the study eye.~8. Uncontrolled systemic disease that could hinder follow-up, immunodeficiency, or any other systemic contraindication for steroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4 mg Triamcinolone Acetonide (TA)/ Suprachoriodal Injection (Type: EXPERIMENTAL): Suprachoroidal injection of 4 mg in 100 μL of TA was administered as a single injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL at screening~* Chronic HCV infection (≥ 6 months)~* HCV treatment naive or treatment experienced with an interferon (IFN)-based regimen~* Use of protocol specified methods of contraception~Key Exclusion Criteria:~* Current or prior history of clinically significant illness that may interfere with participation in the study~* Screening ECG with clinically significant abnormalities~* Laboratory parameters outside the acceptable range at screening~* Pregnant or nursing female~* Chronic liver disease not caused by HCV~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL/VOX (Type: EXPERIMENTAL): SOF/VEL/VOX tablet for 8 weeks
- SOF/VEL 12 weeks (Type: ACTIVE_COMPARATOR): SOF/VEL tablet for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy in Reducing Insomnia in Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a confirmed diagnosis of cancer~* Have received surgery, chemotherapy, and/or radiation therapy~* Have completed all surgery, chemotherapy and/or radiation therapy within the last 2-60 months~* Meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-V criteria for insomnia and score \>= 10 on the Insomnia Severity Index~* Be able to read and understand English~* Be able to provide written informed consent~Exclusion Criteria:~* Have contraindications to functional testing or yoga participation according to the treating physician~* Have practiced yoga \>= 1 day a week within the 3 months prior to enrolling in the study~* Be planning to start yoga on their own during the time they are enrolled in the study~* Have a confirmed diagnosis of sleep apnea or restless leg syndrome~* Be receiving any form of treatment for cancer with the exception of hormonal or biologic therapy~* Have distant metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (behavioral intervention-yoga) (Type: EXPERIMENTAL): Patients undergo the YOCAS intervention comprising 18 specific physical postures and mindfulness exercises focused on breathing and meditation and meet with the yoga instructor over 75 minutes 2 times a week for 4 weeks.
- Arm II (cognitive intervention-CBT-I) (Type: EXPERIMENTAL): Patients undergo CBT-I intervention comprising sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention delivered by a health professional over 90 minutes once a week for 8 weeks.
- Arm III (educational intervention) (Type: ACTIVE_COMPARATOR): Patients attend survivorship health education sessions over 75 minutes 2 times a week for 4 weeks based on the American Society of Clinical Oncology cancer survivorship educational recommendations delivered by a community health educator. Patients also receive a booklet entitled, Cancer Survivorship Next Steps for Patients and Their Families.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥ 18 and \< 65 years~* Good general condition (according to history and clinical examination)~* Written informed consent~* No pregnancy~* No breast feeding~* Efficacious contraception (e.g. oral, double-barrier) during the study and 4 weeks after termination of the study~* No participation in other clinical trials 4 weeks before, during participation, and 4 weeks after participation in this study~* Planned travel period between 6 and 28 days~* Planned travel to South- and Southeast Asia~* Planned time to arrival in South- or Southeast Asia ≤ 24 hours~Exclusion Criteria:~* Pregnancy~* Breast feeding~* Age \< 18 and ≥ 65 years~* No written informed consent~* Chronic gastrointestinal disease and/ or immune insufficiency~* Low general condition (according to history and clinical examination)~* Regular medication with gastrointestinal side-effects and/or immunosuppressive medication~* Participation in other clinical trials 4 weeks before, during and 4 weeks after termination of the study~* No efficacious contraception~* Planned travel period \< 6 and \> 28 days~* Planned travel outside South- and Southeast Asia~* Vaccination against cholera using DUKORAL within 12 months prior to inclusion~* Planned time to arrival in South- or Southeast Asia \> 24 hours~* Known hypersensitivity against rifaximin or rifamycin-derivatives in general~* Known lactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): None
- Lactose (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete